153 related articles for article (PubMed ID: 15213877)
1. [Prophylaxis and differential therapy of tumorlysis syndrome].
Krych M; Dreyling M; Kneba M; Hoelzer D; Hiddemann W; Hallek M
Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1440-5. PubMed ID: 15213877
[No Abstract] [Full Text] [Related]
2. Management of hyperuricemia with rasburicase review.
de Bont JM; Pieters R
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
[TBL] [Abstract][Full Text] [Related]
3. The status of allopurinol in the management of tumor lysis syndrome: a clinical review.
Hagemeister F; Huen A
Cancer J; 2005; 11 Suppl 1():S1-10. PubMed ID: 15835720
[No Abstract] [Full Text] [Related]
4. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
5. [Malignant hemopathies and tumor lysis syndrome: a current topic].
Leverger G; Le Guyader N
Arch Pediatr; 2005 Oct; 12 Spec No 1():1-3. PubMed ID: 17076002
[No Abstract] [Full Text] [Related]
6. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
7. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
Holdsworth MT; Nguyen P
Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
[TBL] [Abstract][Full Text] [Related]
8. Management of tumor lysis syndrome in adults.
Coiffier B; Riouffol C
Expert Rev Anticancer Ther; 2007 Feb; 7(2):233-9. PubMed ID: 17288532
[TBL] [Abstract][Full Text] [Related]
9. Tumor lysis syndrome and neuroblastoma.
Milano GM; De Sio L; Cozza R; Donfrancesco A
Med Pediatr Oncol; 2003 Dec; 41(6):592. PubMed ID: 14595729
[No Abstract] [Full Text] [Related]
10. Targeting tumor lysis syndrome: new therapeutic options.
Shonkwiler E
ONS News; 2006; 21(8 Suppl):49-50. PubMed ID: 16925150
[No Abstract] [Full Text] [Related]
11. Uric acid concentrations and the mechanisms of cardiovascular disease.
Waring WS; Maxwell SR; Webb DJ
Eur Heart J; 2002 Dec; 23(23):1888-9. PubMed ID: 12445542
[No Abstract] [Full Text] [Related]
12. Advances in the management of malignancy-associated hyperuricaemia.
Mahmoud HH; Leverger G; Patte C; Harvey E; Lascombes F
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):18-20. PubMed ID: 9647616
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic considerations in the management of acute tumor lysis syndrome.
Farber MS
Semin Oncol; 2001 Apr; 28(2 Suppl 5):19-22. PubMed ID: 11343274
[No Abstract] [Full Text] [Related]
14. Use of single-dose rasburicase in an obese female.
Arnold TM; Reuter JP; Delman BS; Shanholtz CB
Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
[TBL] [Abstract][Full Text] [Related]
15. Clarifying the role of rasburicase in tumor lysis syndrome.
Sood AR; Burry LD; Cheng DK
Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
[TBL] [Abstract][Full Text] [Related]
16. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
[TBL] [Abstract][Full Text] [Related]
17. Tumor lysis syndrome, case report and review of the literature.
Masera G; Jankovic M
Ann Oncol; 1997 Jan; 8(1):97. PubMed ID: 9093714
[No Abstract] [Full Text] [Related]
18. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
Cairo MS; Thompson S; Tangirala K; Eaddy MT
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
[TBL] [Abstract][Full Text] [Related]
19. [The current status of the treatment of tumor lysis syndrome--the role of rasburicase (Fasturtec)].
Urbieta M
Arch Pediatr; 2005 Oct; 12 Spec No 1():8-12. PubMed ID: 17076004
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Patel S; Le A; Gascon S
Am J Health Syst Pharm; 2012 Jun; 69(12):1015-6. PubMed ID: 22644973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
